Could a heart drug fix metabolism in black obesity?
NCT ID NCT06320951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether vericiguat, a drug already used for heart failure, can improve how the body uses sugar and burns energy in Black adults with obesity and insulin resistance. Researchers will give 200 participants either vericiguat or a placebo daily for 12 weeks, measuring changes in insulin sensitivity and energy expenditure. The goal is to see if boosting a natural signaling pathway can lower the risk of heart disease and diabetes in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vericiguat (a drug that boosts a natural signaling pathway to improve metabolism)
What this could lead to
If it works, this could point toward a new way to reduce heart disease and diabetes risk in Black individuals with obesity.
What could go wrong
This is an early phase 2 trial with only 200 people over 12 weeks. It may not show clear benefits, and results may not apply to other groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States